Fhl1 - four and a half LIM domains 1

Predicted to enable transmembrane transporter binding activity. Predicted to be involved in several processes, including negative regulation of mitotic cell cycle phase transition; regulation of membrane depolarization; and regulation of potassium ion transport. Predicted to act upstream of or within cell differentiation. Predicted to be located in cytosol; nucleus; and plasma membrane. Is expressed in several structures, including alimentary system; brain; cardiovascular system; genitourinary system; and sensory organ. Used to study scapuloperoneal myopathy. Human ortholog(s) of this gene implicated in Uruguay faciocardiomusculoskeletal syndrome; X-linked Emery-Dreifuss muscular dystrophy 6; reducing body myopathy 1A; and reducing body myopathy 1B. Orthologous to human FHL1 (four and a half LIM domains 1). [provided by Alliance of Genome Resources, Apr 2022]